CBDA and CBGA hemp compounds found to fight COVID-19

New search which is creating all the buzz has discovered that two compounds commonly found in hemp have the potential to fight the SARS-CoV-2 coronavirus. The compounds, cannabidiolic acid, or CBDA, and cannabigerolic acid, or CBGA, block a critical step in the process the virus uses to infect people.

No, that doesn’t mean you can smoke weed and prevent ‘rona’.

No, that doesn’t mean you can inject CBD oil from that tincture bottle and keep the video at bay.

CBDA and CBGA are not found in commercial CBD hemp products.

“The ‘A’ forms, which are the acidic forms, of CBD and CBG are not typically present in most commercially available hemp products,” said Lynda LeMole, product industry consultant. natural. “The acid forms are found in the fresh plant. There are processes that stabilize the acid forms, so you should consult the product test analysis to see if the acid forms are still present in the final product.

Both compounds were identified by chemical screening. The compounds bind to spike proteins found on the virus and prevent the spike protein from binding to sites on a human host, thereby preventing a step the pathogen uses to infect people.

“The sour forms are grossly underestimated,” says cannabis consultant Richard Rose. “Even non-stony THCA.”

The heat inactivates the compounds and renders them unable to bind to the spike protein. That’s why smoking marijuana wouldn’t work.

The researchers used the alpha and beta viral forms of the SARS-CoV-2 virus, not the latter-day delta variant or the current omicron variant.

But the researchers are confident that these and future variants could be counteracted in the same way by CBDA and CBGA.

“Regarding activity against other variants of the virus, we hope that activity against the original strain and two early variants could mean activity against subsequent strains,” said lead researcher Richard van Breemen. , Ph.D., to Insider. Van Breemen is a professor of pharmaceutical sciences at the Linus Pauling Institute and College of Pharmacy at the Global Hemp Innovation Center at Oregon State University. “This experiment, however, remains to be done.”

Even so, research continues the story of various natural products, such as vitamin D, zinc and quercetin, which can be used as therapeutic agents against the pandemic. It also demonstrates the burgeoning possibilities of cannabinoid medicine now that the plant is freed from the clutches of a nearly century-old lockdown.

“We are only scratching the surface of what we know about cannabinoid mothers and CBD family minors, and the positive and effective impacts this can have on preventive and therapeutic care, including CBD-based diseases. virus, as research indicates,” said Thom Brodeur. , CEO of Sky Wellness, a CBD brand. “There is more research to be done, more ground to cover and more to discover that could, as this recent research suggests, show us cases of use and value for CBD and its derivatives that have been under our nose all this time. This is the exciting part.

Van Breemen agrees that the door has just been opened to hemp research.

“Hemp is a rich source of plant secondary metabolites, many of which are unique and not found in other organisms,” he said. “CBD has already been approved by the FDA for the treatment of certain juvenile forms of epilepsy. Our findings suggest that other cannabinoids may also have medicinal properties.

A major obstacle remaining is that of the FDA, which gives every indication that it would prefer that cannabinoid drugs be made available to the public only through pharmaceutical drug pipelines and not through the more promiscuous route of food supplements.

Not a week after the Oregon research was disclosed, the FDA approved the use in clinical trials of a CBD-based treatment for opioid use disorder. Scientific Ananda, the drug’s maker, has obtained an Investigational New Drug (IND) designation for Nantheia ATL5 from the FDA.

Comments are closed.